Trial of pegylated liposomal doxorubicin versus bleomycin and vincristine inside the therapy of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998; 16:683?91. [PubMed: 9469358]Author Manuscript Author Manuscript Author Manuscript Author ManuscriptCurr Opin HIV AIDS. Author manuscript; readily available in PMC 2018 December 31.Goncalves et al.Page51. Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi’s sarcoma. Oncologist. 2007; 12:114?23. [PubMed: 17227906] 52. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: proof of symptom palliation from chemotherapy. Cancer. 2010; 116:3969?977. [PubMed: 20564162] 53. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine within the remedy of AIDS-related Kaposi’s sarcoma: final results of a randomized phase III clinical trial. J Clin Oncol. 1998; 16:2445?451. [PubMed: 9667262] 54. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol. 1998; 16:1112?1121. [PubMed: 9508198] 55. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in individuals with advanced AIDS-related Kaposi sarcoma. Cancer. 2002; 95:147?54. [PubMed: 12115328] 56. Polizzotto MN, Uldrick T, Wyvill K, et al. Pomalidomide for Kaposi Sarcoma in people with and with out HIV: A phase I/II study. J. Clinical Oncology. 2016 * Pomalidomide was properly tolerated in patients with KS (both with and without having HIV infection) at 5mg orally every day for 21 out of 28 days. The general response price was 68 , with 18 full responses. 57. Polizzotto MN, Sereti I, Uldrick T, et al. Pomalidomide induces expansion of activated and central memory CD4+ and CD8+ T cells in vivo in sufferers with and devoid of HIV infection. Blood. 2014; 124:4128?128. * Sufferers with Kaposi sarcoma treated with pomalidomide showed substantial increases within the number of CD4 and CD8 T cells. 58. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an efficient and secure drug for AIDS-related Kaposi’s sarcoma: outcomes of a phase II study. J Clin Oncol. 2000; 18:1550?557.2-Ethynyl-1,1′-biphenyl manufacturer [PubMed: 10735904] 59.170097-87-7 supplier Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study.PMID:35991869 J Clin Oncol. 2002; 20:3236?241. [PubMed: 12149296] 60. Iuliano F, Cervo G, Iuliano E, et al. Weekly nab-paclitaxel in elderly individuals with classic Kaposi sarcoma. 2016 American Society of Clinical Oncology Annual Meeting. 2016Abstract e22539 * Post describing the usage of weekly nab-paclitaxel in elderly sufferers with classic KS as an effective and much less toxic regimen for this patient population. 61. Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIVassociated Kaposi’s sarcoma getting antiretroviral therapy. J Clin Oncol. 2012; 30:1476?483. [PubMed: 22430271] 62. Koon HB, Krown SE, Lee JY, et al. Phase II trial of imatinib in AIDS-associated Kaposi’s sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol. 2014; 32:402?08. [PubMed: 24378417] * Imatinib has activity.